RT Journal Article
T1 Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
A1 Salvador-Martin, Sara
A1 Kaczmarczyk, Bartosz
A1 Alvarez, Rebeca
A1 Navas-Lopez, Victor Manuel
A1 Gallego-Fernandez, Carmen
A1 Moreno-Alvarez, Ana
A1 Solar-Boga, Alfonso
A1 Sanchez, Cesar
A1 Tolin, Mar
A1 Velasco, Marta
A1 Muñoz-Codoceo, Rosana
A1 Rodriguez-Martinez, Alejandro
A1 Vayo, Concepcion A
A1 Bossacoma, Ferran
A1 Pujol-Muncunill, Gemma
A1 Fobelo, Maria J
A1 Millan-Jimenez, Antonio
A1 Magallares, Lorena
A1 Martinez-Ojinaga, Eva
A1 Loverdos, Ines
A1 Eizaguirre, Francisco J
A1 Blanca-Garcia, Jose A
A1 Clemente, Susana
A1 Garcia-Romero, Ruth
A1 Merino-Bohorquez, Vicente
A1 Gonzalez-de-Caldas, Rafael
A1 Vazquez, Enrique
A1 Dopazo, Ana
A1 Sanjurjo-Saez, Maria
A1 Lopez-Fernandez, Luis A
K1 Crohn disease
K1 Adalimumab
K1 Biomarker
K1 Gene expression
K1 Inflammatory bowel disease
K1 Infliximab
K1 Ulcerative colitis
K1 Área de Gestión Sanitaria Sur de Sevilla
AB Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged  Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or 0.6 or  Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
PB MDPI
SN 1999-4923
YR 2021
FD 2021-01-08
LK http://hdl.handle.net/10668/16953
UL http://hdl.handle.net/10668/16953
LA en
NO Salvador-Martín S, Kaczmarczyk B, Álvarez R, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, et al. Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Pharmaceutics. 2021 Jan 8;13(1):77
NO This research was funded by Instituto de Salud Carlos III (grants numbers PI16/00559 and PI19/00792), Consejería de Educación y Deporte de la Comunidad de Madrid (grant number PEJ16/MED/AI-1260), and by the Gregorio Marañón Health Research Institute (grant number PRE2018-2). The study was cofunded by European Regional Develompment Funds (FEDER) from theEuropean Commission, “A way of making Europe”.
DS RISalud
RD Apr 13, 2025